Premium
Development of new prostate specific monoclonal antibodies
Author(s) -
Lampe M.I.,
MolkenboerKuenen J.D.M.,
Oosterwijk E.
Publication year - 2003
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10326
Subject(s) - monoclonal antibody , prostate cancer , prostate , antigen , prostate specific antigen , immunohistochemistry , cancer , antibody , medicine , epitope , monoclonal , immunology , cancer research , pathology
BACKGROUND Despite the need for new prostate‐specific diagnostic and therapeutic targets, very few unique prostate (cancer) specific antigens have been characterized. Monoclonal antibody (mAb) technology is a powerful tool to identify specific antigenic markers, which could be potential targets for cancer diagnostics or therapy. METHODS Splenocytes from mice immunized with prostate cancer (PCa) homogenates of different origin were fused using standard techniques. Employing a differential high‐throughput screening method followed by immediate screening in immunohistochemistry (IHC) a large number of hybridomas were screened for prostate (cancer) specificity. RESULTS From 25 successful fusions approximately 300 clones were identified excreting PCa‐reactive antibodies. Subsequent immunohistochemical fine‐specificity analysis reduced this number to 26. Eventually, after extensive fine‐specificity analysis, the number of mAbs appearing to define prostate‐specific antigenic structures that might serve as new diagnostic or therapeutic targets was reduced to three. CONCLUSIONS Using mAb technology combined with a high throughput screening method we have developed three mAbs (1.8, 2.26, and 3.10) directed against prostate associated antigens that might identify potential new therapeutic targets. © 2003 Wiley‐Liss, Inc.